Lista de obras -

A Bayesian multivariate joint frailty model for disease recurrences and survival.

artículo científico publicado en 2016

A flexible and robust method for assessing conditional association and conditional concordance

artículo científico publicado en 2019

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

artículo científico publicado en 2017

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2008

A two-stage approach for dynamic prediction of time-to-event distributions.

artículo científico publicado en 2016

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

artículo científico publicado en 2016

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

artículo científico publicado en 2013

An oncology clinical trial design with randomization adaptive to both short- and long-term responses.

artículo científico publicado en 2017

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

artículo científico publicado en 2017

BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia

scientific article published on 03 October 2013

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

artículo científico publicado en 2015

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 29 de noviembre de 2010

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

scientific article published on 11 October 2018

Clofarabine combinations as acute myeloid leukemia salvage therapy

artículo científico publicado en 2008

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients ⬇️

artículo científico publicado el 26 de enero de 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

artículo científico publicado en 2016

Comparing Bayesian early stopping boundaries for phase II clinical trials

artículo científico publicado en 2020

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

artículo científico publicado en 2008

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis

artículo científico publicado en 2009

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

artículo científico publicado en 2013

Dynamic prediction of time to a clinical event with sparse and irregularly measured longitudinal biomarkers

scientific article published on 20 March 2020

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

artículo científico publicado en 2010

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Estimation of the distribution of longitudinal biomarker trajectories prior to disease progression

artículo científico publicado en 2019

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

artículo científico publicado en 2012

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome ⬇️

artículo científico publicado el 24 de febrero de 2012

Functional principal component based landmark analysis for the effects of longitudinal cholesterol profiles on the risk of coronary heart disease

artículo científico publicado en 2020

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

artículo científico publicado en 2020

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

artículo científico publicado en 2018

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

artículo científico publicado en 2017

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

MYC protein expression is an important prognostic factor in acute myeloid leukemia

artículo científico publicado en 2018

Mean residual life regression with functional principal component analysis on longitudinal data for dynamic prediction

artículo científico publicado en 2018

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs

artículo científico publicado en 2015

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

artículo científico publicado en 2017

Optimization of multi-stage dynamic treatment regimes utilizing accumulated data

artículo científico publicado en 2015

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

artículo científico publicado en 2016

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

artículo científico publicado en 2014

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

artículo científico publicado en 2011

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

artículo científico publicado en 2016

Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

artículo científico publicado en 2020

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia

scientific article published on 28 February 2014

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

artículo científico publicado en 2014

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

artículo científico

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

artículo científico publicado en 2015

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Quantile residual lifetime regression with functional principal component analysis of longitudinal data for dynamic prediction.

artículo científico publicado en 2018

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

artículo científico publicado en 2010

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2006

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

artículo científico publicado en 2014

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

artículo científico publicado en 2018

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2014

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

artículo científico publicado en 2017

Semiparametric accelerated failure time cure rate mixture models with competing risks

artículo científico publicado en 2017

Semiparametric modelling and estimation of covariate-adjusted dependence between bivariate recurrent events

scientific article published on 28 January 2020

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

artículo científico publicado en 2017

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

artículo científico publicado en 2007

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

artículo científico publicado en 2012

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

scientific article published on 14 July 2020

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

artículo científico publicado en 2007

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12 ⬇️

artículo científico publicado el 25 de agosto de 2011

Lista de obras de

A Bayesian multivariate joint frailty model for disease recurrences and survival.

A flexible and robust method for assessing conditional association and conditional concordance

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

A two-stage approach for dynamic prediction of time-to-event distributions.

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

An oncology clinical trial design with randomization adaptive to both short- and long-term responses.

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia ⬇️

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

Clofarabine combinations as acute myeloid leukemia salvage therapy

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients ⬇️

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Comparing Bayesian early stopping boundaries for phase II clinical trials

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Dynamic prediction of time to a clinical event with sparse and irregularly measured longitudinal biomarkers

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Eradication of minimal residual disease in hairy cell leukemia

Estimation of the distribution of longitudinal biomarker trajectories prior to disease progression

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome ⬇️

Functional principal component based landmark analysis for the effects of longitudinal cholesterol profiles on the risk of coronary heart disease

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Mean residual life regression with functional principal component analysis on longitudinal data for dynamic prediction

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

Optimization of multi-stage dynamic treatment regimes utilizing accumulated data

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

Quantile residual lifetime regression with functional principal component analysis of longitudinal data for dynamic prediction.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

Semiparametric accelerated failure time cure rate mixture models with competing risks

Semiparametric modelling and estimation of covariate-adjusted dependence between bivariate recurrent events

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12 ⬇️